Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-12-01 Epub Date: 2023-11-13 DOI:10.2217/pgs-2023-0198

Sara Gagno, Chiara Dalle Fratte, Bianca Posocco, Angela Buonadonna, Arianna Fumagalli, Michela Guardascione, Giuseppe Toffoli, Erika Cecchin

引用次数: 0

Abstract

Tweetable abstract Present evidence supports the use of intensified pharmacologic monitoring of #imatinib including #TherapeuticDrugMonitoring and #PGx to improve outcomes in patients with GI stromal tumor. Future studies need to address emerging questions to facilitate implementation in clinics.

查看原文本刊更多论文

调节胃肠道间质瘤患者伊马替尼暴露的治疗药物监测和药物遗传学:临床实施的障碍和前景。

现有证据支持强化伊马替尼的药理学监测，包括#TherapeuticDrugMonitoring和#PGx，以改善胃肠道间质瘤患者的预后。未来的研究需要解决新出现的问题，以促进在诊所的实施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.